{'fraction_non_alphanumeric': 0.03761242845461979, 'fraction_numerical': 0.03107113654946852, 'mean_word_length': 4.589041095890411, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nonsurgical alternative therapy for bulky advanced head and neck tumors.

OBJECTIVE
To rapidly induce symptomatic relief and local tumor control in bulky advanced head and neck tumors without surgery.


DESIGN
A retrospective analysis of the results with palladium 103-labeled or iodine 125-labeled brachytherapy (BT) and adjunctive external beam radiation therapy (EBRT); a survival analysis by the Kaplan-Meier method; and a comparison of results between the BT/EBRT and EBRT/BT (or BT alone) groups by the log-rank test. A nonsurgical alternative therapy was given to a total of 51 patients who presented with tumors of more than 100 cm3 in volume.


RESULTS
Moderate to complete symptomatic relief was observed in 31 (61%) of 51 patients. Seven (33%) of 21 patients in the BT/EBRT group and two (7%) of 30 in the EBRT/BT group were recurrence-free at 36 months. The difference was significant by the log-rank test. Cause-specific and overall 36-month survivals were 23% and 5%, respectively.


CONCLUSION
Cure rate by conventional therapy in bulky advanced head and neck tumors is dismal. The palladium 103- or iodine 125-BT/EBRT offers good symptomatic relief and an acceptable probability of recurrence-free survival.